In the same token, the Hh antagonist Vismodegib, a cyclopamine derivative that binds SMO preventing Gli activation and macrophage recruitment modifier, is a clinically approved therapy to treat BCC and is undergoing phase II clinical trials for medulloblastoma and other cancers (Gampala et al., 2021) [NCT00833417]. This evidence concerns the gene GLI1 and medulloblastoma.